Status:
TERMINATED
Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury
Lead Sponsor:
Frederick Health
Conditions:
Covid-19
ARDS, Human
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19
Detailed Description
COVID-19 is a novel coronavirus that can cause severe and potentially fatal respiratory infections. COVID-19 has many similarities to previously seen coronaviruses, such as those that caused the Middl...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Admitted to the intensive care unit
- Positive COVID-19 PCR
- Mechanical Ventilation for ≤ 48 hours
- PaO2/FiO2 ≤300
Exclusion
- Heparin allergy
- Active bleeding
- Death or withdraw of care anticipated by intensivist within 24 hours
- Platelets\< 50,000 cells/µL
- Clinically significant coagulopathy, as decided by the intensivist
- O2 dependent at baseline
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04397510
Start Date
June 1 2020
End Date
December 31 2021
Last Update
April 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Frederick Health Hospital
Frederick, Maryland, United States, 21701